Newsroom

Newsroom

Featured News

 

Date Title and Summary
Toggle Summary CTV News - Safely Skipping Chemotherapy
Toggle Summary Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castration-Resistant Prostate Cancer
Medicare Draft Coverage Supports Clinical Utility of the Oncotype DX AR-V7 Nucleus Detect Test, Providing 25,000 Medicare Patients with Coverage Once LCD Is Finalized
Toggle Summary Genomic Health Expands Offering to Prostate Cancer Patients with Launch of Oncotype DX® AR-V7 Nucleus Detect™ Test to Predict Treatment Response in Metastatic Disease
New Liquid Biopsy Test Helps Physicians Select Most Effective Treatment, Prolonging Lives of Men with Metastatic Castration-resistant Prostate Cancer
Toggle Summary German Health Technology Assessment Body (IQWiG) Concludes Only Oncotype DX® has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results
Updated Assessment of Breast Cancer Gene Expression Profiling Tests for Clinical Use in Germany Final German Federal Joint Committee (G-BA) Reimbursement Decision Expected by End of 2018 REDWOOD CITY, Calif. , Sept. 7, 2018 /PRNewswire/ --  Genomic Health, Inc.  (NASDAQ: GHDX) today announced the

Latest Press Releases

Date Title and Summary
Toggle Summary Genomic Health and Biocartis Announce Agreement to Develop an Idylla™ IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access
Strategic Collaboration Aimed at Exclusive Test Development and Commercialization of Proprietary Genomic Health Tests on the Idylla™ Platform
Toggle Summary Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla™ Oncotype DX® Genomic Prostate Score® Test
REDWOOD CITY, Calif. and MECHELEN, Belgium , Dec. 3, 2018 /PRNewswire/ --  Genomic Health , Inc. (NASDAQ: GHDX), the world's leading provider of genomic-based diagnostic tests and Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced they have
Toggle Summary Genomic Health and Cleveland Diagnostics Announce Strategic Collaboration to Develop and Commercialize New Prostate Cancer Tests
Global Licensing Agreement Provides Genomic Health with Exclusive Rights to Cleveland Diagnostics' Proprietary IsoPSA™ Technology
Toggle Summary Genomic Health Announces 2017 Fourth Quarter and Year-end Financial Results, Provides 2018 Financial Outlook
Achieved $1.9M Profit in the Fourth Quarter; Reported Net Loss of $3.9M for the Full Year Delivered $0.4M Full-year Profit on a Non-GAAP Basis Excluding Business Development Transaction Costs Delivered 7 Percent Test Growth and 6 Percent Revenue Growth in the Fourth Quarter Guides to Double-digit Revenue Growth and Full-year Profitability in 2018

Patient & Physician Stories

 

 
 

Your Prostate, Your Decision: A Patient's Perspective

1559 views 09/24/2014

Watch the Video

Do You Know Your Oncotype DX Score?

174 views 09/29/2015

Watch the Video

Oncotype DX DCIS Breast Cancer Score: Amy's Story

8370 views 07/17/2013

Watch the Video

An Oncotype DX Breast Cancer Treatment Story from Mexico (MX)

644 views 11/13/2012

Watch the Video

Dr. Peter Carroll on the Validation of the Oncotype DX Prostate Cancer Test

299 views 12/08/2015

Watch the Video

Dr. Joseph Sparano on the Necessity of Oncotype DX Genomic Testing in Breast Cancer

164 views 12/08/2015

Watch the Video

 

Social Media

Learn About the Oncotype DX Prostate Cancer Test

13600 views 05/04/2013

Watch the Video

Genomic Health and Oncotype IQ – Delivering Precision Medicine

67 views 09/06/2018

Watch the Video

Oncotype DX AR-V7 Nucleus Detect test

528 views 08/10/2018

Watch the Video